Boston Scientific to Acquire Remaining Bolt Medical Stake for $664M

Boston Scientific has agreed to acquire Bolt Medical for $664 million, comprising a $443 million upfront payment and up to $221 million contingent on achieving regulatory milestones. Bolt specializes in laser-based IVL technology, which uses acoustic pressure waves within a balloon catheter to break up calcified masses in arteries, restoring blood flow. Boston Scientific initially developed the IVL concept and helped establish Bolt in 2019, already holding a 26% equity stake. The acquisition aligns with Boston Scientific's strategy to expand its interventional cardiology portfolio, targeting the growing IVL market.

This acquisition continues Boston Scientific's aggressive M&A activity, following its purchases of Axonics, Silk Road Medical, and other companies in 2024. With Bolt's IVL technology recently yielding promising results in pivotal trials for above- and below-the-knee applications, Boston Scientific plans to use the data to secure FDA and CE mark approvals. While the deal is expected to be slightly dilutive to 2025 adjusted earnings, Boston Scientific anticipates offsetting the impact through cost efficiencies, reinforcing its leadership in cardiovascular care.